BridgeBio Pharma (BBIO) EBITDA Margin (2019 - 2026)
BridgeBio Pharma recorded quarterly EBITDA Margin of 54.47% in Q1 2026, up 39.82% quarter-over-quarter from 90.52% in Q4 2025, and up 3502.0% year-over-year from 1.51% in Q1 2025.
BridgeBio Pharma's EBITDA Margin history runs 8 years deep, the most recent figure standing at 54.47% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 3502.0% year-over-year to 54.47%; the TTM figure through Mar 2026 stood at 90.52% (up 45705.0% YoY), while the FY2025 annual figure was 104.25%, up 16297.0% from the prior year.
- EBITDA Margin came in at 54.47% for Q1 2026 at BridgeBio Pharma, up from 90.52% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 0.16% in Q1 2024 to a low of 38200.0% in Q3 2022.
- A 5-year average of 6161.19% and a median of 3854.61% in 2023 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin sank 3182206 bps in 2022 and surged 3434539 bps in 2023, its largest moves.
- BridgeBio Pharma's EBITDA Margin stood at 6910.8% in 2022, then sank by 47 bps to 10167.11% in 2023, then soared by 62 bps to 3842.69% in 2024, then jumped by 98 bps to 90.52% in 2025, then jumped by 40 bps to 54.47% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 54.47%, 90.52%, and 120.3% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -54.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54.47% |
| Dec 31, 2025 | -90.52% |
| Sep 30, 2025 | -120.30% |
| Jun 30, 2025 | -121.45% |
| Mar 31, 2025 | -89.49% |
| Dec 31, 2024 | -3,842.69% |
| Sep 30, 2024 | -7,018.67% |
| Jun 30, 2024 | -8,096.82% |
| Mar 31, 2024 | 0.16% |
| Dec 31, 2023 | -10,167.11% |
| Sep 30, 2023 | -3,854.61% |
| Jun 30, 2023 | -8,903.05% |
| Mar 31, 2023 | -6,909.26% |
| Dec 31, 2022 | -6,910.80% |
| Sep 30, 2022 | -38,200.00% |
| Jun 30, 2022 | -108.72% |
| Mar 31, 2022 | -10,252.54% |
| Dec 31, 2021 | -1,656.14% |
| Sep 30, 2021 | -6,377.94% |
| Jun 30, 2021 | -1,106.06% |
| Mar 31, 2021 | -36,256.28% |
| Dec 31, 2020 | -104,499.18% |
| Sep 30, 2020 | -1,475.81% |
| Sep 30, 2019 | -204.24% |